Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (23045)	1/28/2000 12:29:00 PM
From: LANCE B	Read Replies (1) \| Respond to of 150070

BCAM-THIS IS BIG...STOCK ON THE VERGE OF A BREAKOUT...SMALL UPTICKS EVERYDAY AND EXCELLENT NEWS THAT NOBODY REALLY CAUGHT.. (COMTEX) B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRAT B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRATEGY FOR DISTRIBUTING THE LUNGCHECK(R) CANCER SCREENING PROGRAM OVER THE Internet MELVILLE, N.Y., Jan 13, 2000 /PRNewswire via COMTEX/ -- BCAM International, Inc. (OTC Bulletin Board: BCAM) announced the following: On January 13, 2000, LungCheck Health, Inc. ("LungCheck"), a wholly owned subsidiary of BCAM International, Inc. announced its new plans to become the preeminent provider of pulmonary disease programs and information to consumers on the Internet. The Company plans to promote its proprietary quantitative sputum cytology test, LungCheck(R), directly on its own website (http://www.lungcheck.com) as well as through other leading web portals that service the healthcare consumer. The Company's innovative "e-health" strategy includes the utilization of a nationwide physician network through partnerships with leading disease management companies and world-renowned medical institutions. These partnerships will provide the necessary physician oversight for the ordering and reporting of LungCheck(R) test results and follow-up care for patients requesting the test in each state. LungCheck is a pulmonary pathology product and services company specializing in early lung disease screening and the assessment of lung health through the utilization of its proprietary quantitative sputum cytology test and program called LungCheck(R). The Company currently distributes its LungCheck(R) Sputum Cytology Test and Program through partnerships with leading providers of testing services to Fortune 500 Companies as part of their corporate wellness and/or screening programs. The Company also distributes its sputum test and program to large medical clinics where it has been successfully used as a biofeedback mechanism to aid in smoking cessation and as a monitoring tool for patients who have a family history of pulmonary disease or are recovering from cancer. LungCheck is also used to monitor employees who work in environments where they may be exposed to pulmonary irritants. In addition to its newly designed e-health sales strategy, the Company will continue to distribute its test and program to other Fortune 500 Corporations, leading medical clinics as well as non-corporate organizations such as unions and the military, which are part of the occupational health market. The LungCheck(R) Sputum Cytology Test is one of the most cost-effective, non-invasive screening tools for lung cancer and other pulmonary diseases on the market providing both early detection and patient monitoring capabilities. Conventional chest x-ray and bronchoscopy are routinely used to diagnose lung cancer, but several studies suggest that these techniques are often less sensitive than sputum cytology in detecting lung cancer in its the earliest stages. Like cervical cancer, if detected early (prior to detecting cancer cells in sputum; i.e. severe dysplasia), lung cancer can be treated successfully in more than 50% of the cases according to the National Cancer Institute (NCI). In 1999, lung cancer (not including other forms of lung disease) was responsible for approximately 160,000 deaths, with 170,000 new cases diagnosed in the United States. Based on the long-term success of the Pap Smear for early detection of cervical cancer, Management believes that LungCheck(R), a tool that can be compared to a "Pap Smear" for the lungs, is an equally valuable tool to be used for the early detection and monitoring of pulmonary disease. The Company conservatively estimates that the United States market for the LungCheck(R) Test is in excess of $1 billion. "LungCheck Health has begun the process of aggressively marketing its screening program to large groups of potential users who show signs of being at serious risk for lung disease due to their work environment or because of smoking. We are extremely excited about our e-health strategy because it gives consumers information on-line on how to quickly access and participate in the program and perform the specimen collection at home, while remaining connected and under the supervision of the best pulmonary medical specialists in the country. Unlike most healthcare businesses launching business on the Internet, our Company has a program being used by physicians currently that will continue over the next several years to significantly impact the paradigm for lung disease management," said Michael Strauss, CEO and Chairman of LungCheck Health, Inc., a subsidiary of BCAM International, Inc. He continues, "I truly believe that as consumers become increasingly empowered through their use of the Internet, our growth as a company will be significantly advanced. Several of the Company's key investors have demonstrated their continued support of our business strategies through additional investments in the Company. Consequently, we have been provided the opportunity to become extremely aggressive in the marketplace and to establish ourselves as the leading provider of testing programs and pulmonary disease related information to consumers on the Internet." The Company's common stock appears on the OTC Bulletin Board. The forward-looking statements included in this news release are based on management's current expectations. In light of the assumption and uncertainties inherent in forward looking information, the inclusion of such information should not be regarded as a representation by the Company or any other person that the plans of the Company will be realized or that positive trends in financial results will occur. SOURCE BCAM International, Inc. (C) 2000 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Michael Strauss of BCAM International, Inc., 516-752-3550 (BCAM) GEOGRAPHY: New York INDUSTRY CODE: MLM HEA CPR SUBJECT CODE: PDT OTC * end of story * (COMTEX) B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRAT B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRATEGY FOR DISTRIBUTING THE LUNGCHECK(R) CANCER SCREENING PROGRAM OVER THE Internet MELVILLE, N.Y., Jan 13, 2000 /PRNewswire via COMTEX/ -- BCAM International, Inc. (OTC Bulletin Board: BCAM) announced the following: